Trials / Withdrawn
WithdrawnNCT02449967
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer: Clinical Trial
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction Angiography（DSA）for pancreatic cancer.
Detailed description
By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction Angiography（DSA）for pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | interventional therapy | pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA） |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2018-06-01
- Completion
- 2020-06-01
- First posted
- 2015-05-21
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02449967. Inclusion in this directory is not an endorsement.